| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response
|
Viale, Giuseppe
|
|
2015
|
24 |
S2 |
p. S23-S25
3 p.
|
artikel
|
| 2 |
Adjuvant endocrine therapy for postmenopausal women: Type and duration
|
Mayer, Erica L.
|
|
2015
|
24 |
S2 |
p. S126-S128
3 p.
|
artikel
|
| 3 |
Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer
|
Mathew, Aju
|
|
2015
|
24 |
S2 |
p. S120-S125
6 p.
|
artikel
|
| 4 |
Big data: Are large prospective randomized trials obsolete in the future?
|
Hudis, Clifford A.
|
|
2015
|
24 |
S2 |
p. S15-S18
4 p.
|
artikel
|
| 5 |
Breast conservative surgery and local recurrence
|
Rezai, Mahdi
|
|
2015
|
24 |
S2 |
p. S100-S107
8 p.
|
artikel
|
| 6 |
Clinical implications of molecular heterogeneity in triple negative breast cancer
|
Lehmann, Brian D.
|
|
2015
|
24 |
S2 |
p. S36-S40
5 p.
|
artikel
|
| 7 |
Clinical implications of the intrinsic molecular subtypes of breast cancer
|
Prat, Aleix
|
|
2015
|
24 |
S2 |
p. S26-S35
10 p.
|
artikel
|
| 8 |
Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy
|
Fontanella, Caterina
|
|
2015
|
24 |
S2 |
p. S84-S87
4 p.
|
artikel
|
| 9 |
Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences
|
Hayes, Daniel F.
|
|
2015
|
24 |
S2 |
p. S6-S10
5 p.
|
artikel
|
| 10 |
Conservative surgery for multifocal/multicentric breast cancer
|
Nijenhuis, Matthijs V.
|
|
2015
|
24 |
S2 |
p. S96-S99
4 p.
|
artikel
|
| 11 |
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes
|
Hart, Christopher D.
|
|
2015
|
24 |
S2 |
p. S136-S142
7 p.
|
artikel
|
| 12 |
Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues
|
Yarnold, John
|
|
2015
|
24 |
S2 |
p. S108-S113
6 p.
|
artikel
|
| 13 |
Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
|
Cuzick, Jack
|
|
2015
|
24 |
S2 |
p. S51-S55
5 p.
|
artikel
|
| 14 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications
|
Harbeck, Nadia
|
|
2015
|
24 |
S2 |
p. S44-S48
5 p.
|
artikel
|
| 15 |
Long term side effects of adjuvant chemotherapy in patients with early breast cancer
|
Tao, Jessica J.
|
|
2015
|
24 |
S2 |
p. S149-S153
5 p.
|
artikel
|
| 16 |
Management of breast cancer in older and frail patients
|
Smith, Ian E.
|
|
2015
|
24 |
S2 |
p. S159-S162
4 p.
|
artikel
|
| 17 |
Management of breast cancer in very young women
|
Rosenberg, Shoshana M.
|
|
2015
|
24 |
S2 |
p. S154-S158
5 p.
|
artikel
|
| 18 |
Molecular segmentation of luminal breast: Reality in 2015?
|
Teo, Zhi Ling
|
|
2015
|
24 |
S2 |
p. S41-S43
3 p.
|
artikel
|
| 19 |
Neoadjuvant clinical trial designs: Challenges of the genomic era
|
Carey, Lisa A.
|
|
2015
|
24 |
S2 |
p. S88-S90
3 p.
|
artikel
|
| 20 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints
|
Yeo, Belinda
|
|
2015
|
24 |
S2 |
p. S78-S83
6 p.
|
artikel
|
| 21 |
Neoadjuvant treatment of breast cancer – Clinical and research perspective
|
Loibl, Sibylle
|
|
2015
|
24 |
S2 |
p. S73-S77
5 p.
|
artikel
|
| 22 |
Obesity, insulin resistance and breast cancer outcomes
|
Goodwin, Pamela J.
|
|
2015
|
24 |
S2 |
p. S56-S59
4 p.
|
artikel
|
| 23 |
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015
|
Zardavas, Dimitrios
|
|
2015
|
24 |
S2 |
p. S143-S148
6 p.
|
artikel
|
| 24 |
Optimal surgical management for high-risk populations
|
King, Tari A.
|
|
2015
|
24 |
S2 |
p. S91-S95
5 p.
|
artikel
|
| 25 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women
|
Colleoni, Marco
|
|
2015
|
24 |
S2 |
p. S11-S14
4 p.
|
artikel
|
| 26 |
Predicting benefit of endocrine therapy for early breast cancer
|
Regan, Meredith M.
|
|
2015
|
24 |
S2 |
p. S129-S131
3 p.
|
artikel
|
| 27 |
Progress in the surgical management of breast cancer: Present and future
|
Morrow, Monica
|
|
2015
|
24 |
S2 |
p. S2-S5
4 p.
|
artikel
|
| 28 |
St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!
|
Senn, Hans-Jörg
|
|
2015
|
24 |
S2 |
p. S1-
1 p.
|
artikel
|
| 29 |
Strategies for developing Ki67 as a useful biomarker in breast cancer
|
Denkert, Carsten
|
|
2015
|
24 |
S2 |
p. S67-S72
6 p.
|
artikel
|
| 30 |
Survivorship care after early breast cancer
|
Kyriakides, Stella
|
|
2015
|
24 |
S2 |
p. S163-S164
2 p.
|
artikel
|
| 31 |
Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer
|
Stover, Daniel G.
|
|
2015
|
24 |
S2 |
p. S132-S135
4 p.
|
artikel
|
| 32 |
Targeting bone microenvironment: Clinical implications
|
Gnant, Michael
|
|
2015
|
24 |
S2 |
p. S49-S50
2 p.
|
artikel
|
| 33 |
Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow
|
Kunkler, Ian H.
|
|
2015
|
24 |
S2 |
p. S114-S119
6 p.
|
artikel
|
| 34 |
The changing role of ER in endocrine resistance
|
Nardone, Agostina
|
|
2015
|
24 |
S2 |
p. S60-S66
7 p.
|
artikel
|
| 35 |
What to expect from high throughput genomics in metastatic breast cancers?
|
Onesti, Concetta Elisa
|
|
2015
|
24 |
S2 |
p. S19-S22
4 p.
|
artikel
|
Tijdschrift beschrijving